Paraoxonase and arylesterase levels in rheumatoid arthritis

dc.contributor.authorIsik, A.
dc.contributor.authorKoca, S. S.
dc.contributor.authorUstundag, B.
dc.contributor.authorCelik, H.
dc.contributor.authorYildirim, A.
dc.date.accessioned2026-08-12T17:29:38Z
dc.date.issued2007
dc.departmentFırat Üniversitesi
dc.description.abstractIt was reported that lipid peroxidation (LPO) products increase in rheumatoid arthritis (RA) patients and increased LPO products reduce many antioxidants. Lipid hydroperoxides (LOOHs) are byproduct of LPO. Paraoxonase (PON), arylesterase (ARE), free sulfhydryl (SH) groups, and ceruloplasmin (CP) are enzymes or proteins with antioxidant characteristics. This study aims to determine the levels of LOOHs and SH, and the activities of PON1, ARE, and CP in RA patients. The study included 47 active RA cases and 23 healthy volunteers. The levels of LOOHs and SH, and the activities of PON1, ARE, and CP were determined using appropriate methods. Student's t test and Spearman's correlation analysis methods were employed in the statistical evaluation. The level of LOOHs was found to be higher (p < 0.001), while the level of SH and the activities of PON1, ARE, and CP were found to be lower (p < 0.001, < 0.001, < 0.01, and < 0.01, respectively) in the RA patient group when compared with the control group. There was a negative correlation between the level of LOOHs and the activity of PON1 in the patient group (r=-0.420 and p < 0.01). The results of our study indicate increased oxidant and decreased antioxidant presence in RA patients. PON1 and ARE are known to have antiatherosclerotic effects in addition to their antioxidant characteristics. As the decrease in these antioxidants, resulting from increased oxidative stress in RA patients, development of atherosclerosis besides tissue injury seems inevitable.
dc.identifier.doi10.1007/s10067-006-0300-8
dc.identifier.endpage348
dc.identifier.issn0770-3198
dc.identifier.issue3
dc.identifier.orcid0000-0001-6621-2450
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid16642406
dc.identifier.scopus2-s2.0-33947628713
dc.identifier.scopusqualityQ1
dc.identifier.startpage342
dc.identifier.urihttps://doi.org/10.1007/s10067-006-0300-8
dc.identifier.urihttps://hdl.handle.net/11508/55767
dc.identifier.volume26
dc.identifier.wosWOS:000243969700011
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofClinical Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectarylesterase
dc.subjectlipid hydroperoxide
dc.subjectparaoxonase
dc.subjectrheumatoid arthritis
dc.titleParaoxonase and arylesterase levels in rheumatoid arthritis
dc.typeArticle

Dosyalar